Fast Five Quiz: Chronic Myelogenous Leukemia Management

Emmanuel C. Besa, MD

September 21, 2022

On the basis of follow-up data from the BFORE, DASISION, and ENESTnd trials, a second-generation TKI (bosutinib, dasatinib, or nilotinib) is the preferred treatment option for patients with intermediate- or high-risk chronic phase CML. According to NCCN guidelines, the first-generation TKI, imatinib, is another recommended (but not preferred) option.

Learn more about treatment protocols for intermediate- or high-risk CML.

1 2 3 4 5 6

Next Section

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Emmanuel C. Besa. Fast Five Quiz: Chronic Myelogenous Leukemia Management - Medscape - Sep 21, 2022.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

Fast Five Quiz: Chronic Myelogenous Leukemia Management

Tables

Authors and Disclosures

Authors and Disclosures

Author(s)

Emmanuel C. Besa, MD

Comments

Email This

Feedback